Curcumin inhibits leptin gene expression and secretion in breast cancer cells by estrogen receptors

Kazem Nejati-Koshki1*, Abolfazl Akbarzadeh2* and Mohammad Pourhassan-Moghaddam1,3

Abstract

Background: Recent studies suggested that leptin as a mitogenic factor might play an important role in the process of initiation and progression of human cancer. Therefore, it could be considered as a target for breast cancer therapy. A previous study has showed that expression of leptin gene could be modulated by activation of estrogen receptors. Curcumin is a diferuloylmethane that has been shown to interfere with multiple cell signaling pathways and extensive research over the last 50 years has indicated this polyphenol can both prevent and treat cancer. Based on the fact that targeting of leptin could be considered as a novel strategy for breast cancer therapy, the aim of this study is the investigation of potentiality of curcumin for inhibition of leptin gene expression and secretion, and also, its link with expression of estrogen receptors.

Methods: Cytotoxic effect of curcumin on T47D breast cancer cells was investigated by MTT assay test after 24 and 48 treatments. Thereafter, the cells treated with different concentrations of curcumin. The levels of leptin, estrogen receptor α and estrogen receptor β genes expression was measured in the treated and control cells by Reverse-transcription real-time PCR. Amount of secreted leptin in the culture medium was also determined by ELISA in both treated and untreated cells. Finally data were statistically analyzed by one-way ANOVA test.

Results: Analysis of MTT assay data showed that curcumin inhibits growth of T47D cells with dose dependent manner. There were also significant difference between control and treated cells in the levels of leptin, estrogen receptor α expression levels and the quantity of secreted leptin that both were decreased in the treated cells compared with control cells.

Conclusion: Based on the results, curcumin inhibits the expression and secretion of leptin and it could probably be used as a drug candidate for the breast cancer therapy through the leptin targeting in the future.

Keywords: Leptin, Curcumin, Breast cancer, T47D cell line

Introduction

Breast cancer is one of the most commonly diagnosed types of cancer among women in 2012 and expected to account for 29% (226,870) of all new cancer cases among women [1]. Many factors are involved in the breast carcinogenesis, including adipocytokines like leptin [2]. Leptin, a 167 amino acids hormone with a molecular mass of 16 kDa, is mainly secreted from adipose tissue [3]. It has central roles in the control of satiety, energy expenditure, food intake, many reproductive processes [4], affecting the metabolic and hematopoietic systems [5]. Beside the synthesis by adipose tissue as the main source [6], there have been identified other sources of leptin in the body including testicles [7], ovaries [6], placenta [8], cartilage and bone cells [9], skeletal muscle [10] and stomach [11]. Furthermore, the mitogenic, transforming or migration-induced properties of leptin have been revealed in various types of cancer [12].
in many different cell types such as smooth muscle cells [12], normal and neoplastic colon cells [13,14]; and also normal and malignant mammary epithelial cells [15,16]. It has been shown that leptin induces growth and transformation in T47D breast cancer cells unlike normal breast epithelial cells [17]. Leptin acts through binding to its receptor known leptin receptor (ObR) located in the target cell membrane [18]. Significantly higher levels of both leptin and ObR expression have been found in cancer tissue relative to non-cancer epithelium [19]. Also, numerous breast cancer cell lines such as MCF-7 and T47D could express leptin and ObR [16]. All these observations confirm that leptin can act not only by endocrine and (or) paracrine action on mammary tumor cells, but also via an autocrine pathway. Additionally, a significant positive correlation has been obtained between leptin and ObR expressions with breast cancer tissue [20]. Therefore, this paracrine-autocrine leptin axis could become a target for leptin-inhibiting drugs in cancer treatment and prevention.

Results of a study showed that the ratio of ERα to ERβ, in human adipose tissue, was significantly correlated with the level of serum leptin in vivo [21]. Thus, ERα and ERβ maybe have different roles in the regulation of leptin expression.

Curcumin (diferuloylmethane), a derivative of turmeric is one of the most commonly used and highly researched phytochemicals. It exhibits promising pharmacological activities and has demonstrated beneficial effects in terms of cancer cell proliferation, growth, survival, apoptosis, migration, invasion, angiogenesis, and metastasis [22]. Considering important roles of leptin in the breast cancer biology, in this study we investigated the possible variations in the leptin secretion and expression as well as expression of ERs in the T47D breast cancer cell line after its treatment with pure curcumin.

Methods
Our study has been conducted on cell lines and it is compatible with Helsinki ethical codes, and it has been approved by ethics committee of our institute.

Chemicals and reagents
Curcumin (Sigma, Germany), MTT (Sigma, Germany), Leptin ELISA kit (Labor diagnostika nord gmbh & co. kg, Germany), Fetal bovine serum (Gibco, USA), Phenol-red free RPMI 1640 with L-glutamine (Gibco, USA), T47D cells (Pasteur Institute of Iran), Sodium bicarbonate (Merck, Germany), Penicillin (SERVA, Germany), Streptomycin (Merck, Germany), Amphotericin B (Merck, Germany), TRIZOL Reagent (Invitrogen, USA), First-Strand Synthesis kit (Fermentas, USA), Syber Green-I reagent (Fermentas, USA).

Cell culture
T47D cells were cultured in RPMI1640 (with glutamine) supplemented with 10% FBS, penicillin, streptomycin and amphotericin B and incubated at 37°C in a humidified atmosphere containing 5% CO2.

MTT assay and cell treatment
The cytotoxic effect of curcumin on T47D cells was studied by 24 and 48 MTT assays. Briefly, 2500 cell/well were cultivated in a 96 well culture plate. After 24 h incubation in 37°C cells were treated with different concentrations of curcumin (0 to 100 μM) for 24 and 48 h in the quadruplicate manner. Then, medium of all wells were removed carefully and 50 μl 2 mg/ml MTT was added to each well and incubated for 4.5 h, followed by addition of 200 μl DMSO. Thereafter, Sorensen’s glycine buffer was added and absorbance of each well was read at 570 nm. For data analysis, mean OD of each well was calculated. Then, percent of cells viability was calculated according to this formula: percent of cells viability = mean OD of test wells/mean OD of control wells x 100. Finally, a graph was plotted using SPSS 16.0 and IC50 of curcumin on T47D was determined on graph [23].

For studying the inhibitory effect of curcumin on leptin, ERα and ERβ expression as well as leptin secretion, 1×10^5 cells/wells were treated in a 6-well plate with different concentrations of curcumin (0, 10, 20, 30 and 40 μM) for 24-48 h. A control group containing 0.1% DMSO without curcumin served as vehicle control.

Isolation of total RNA and cDNA synthesis
Total RNA was extracted from attached cells using TRIZOL Reagent according to the manufacturer’s instructions. The concentration of prepared RNA was measured using a NanoDrop spectrophotometer (Termoscientific, USA) and its integrity was confirmed by electrophoresis on 1.5% agarose gel containing 1% formaldehyde. After RNA preparation, cDNA was synthesized using the First-Strand Synthesis kit according to the manufacturer’s instructions. The synthesized cDNA was immediately used in a real-time PCR or stored at −70°C for later use.

Real-time PCR
The real-time PCR was used for measurement of leptin, ERα, and ERβ expression levels in the control and treated cells. β-actin gene expression was used as the internal control. The real-time PCR reaction was done using the Syber Green-I reagent in the Rotor Gene 6000 system (Corbett research, Australia) according to the manufacturer’s instructions in a triplicate manner. The amplification conditions were as follows: leptin (2 min at 95°C and a two-step cycle of 95°C for 15 s
and 60°C for 40 s for 40 cycles), ERα (5 min at 95°C and a two-step cycle of 95°C for 30 s and 57°C for 40 s for 40 cycles), and ERβ (5 min at 95°C and a two-step cycle of 95°C for 15 s and 64°C for 40 s for 40 cycles). Sequences of used primers were shown in Table 1. Changes in leptin, ERα, and ERβ expression levels between the control and treated T47D cells were calculated by the $2^{ΔΔCT}$ method.

### Measurement of the secreted leptin
For analysis of possible effect of curcumin on amount of secreted leptin in the treated cells compared with the control cells, leptin concentration was measured in the supernatant media of cells using a human leptin ELISA kit according to the manufacturer’s instructions.

### Table 1 Primers used for real-time PCR amplifications

| Primer   | Primer length | Sequence (5’ to 3’)              | Product size (bp) |
|----------|---------------|----------------------------------|------------------|
| Leptin forward | 22            | CACCAAAAACCTCATCAAGACA          | 80               |
| Leptin reverse | 24            | CTTTCGTGTTGGAGGAGACTGACT        |                  |
| ERα forward   | 20            | GCCAGCAGGTGCCTACTAC             | 132              |
| ERα reverse   | 23            | TGGTACTGGCCAATCTTTCTCTG         |                  |
| ERβ forward   | 19            | AAGAGCTGCCAGGCTGCC              | 268              |
| ERβ reverse   | 21            | GCCAAGGGGACGGCTGA               |                  |
| B-actin forward | 20           | TGGACTCGAGCAAGAGATG            | 137              |
| B-actin reverse | 20           | GAAGGAAGCTGGAAGAGTG           |                  |

Figure 1 The cytotoxic effect of curcumin on T47D cells during 24 h (A) and 48 h MTT assays.
Statistical analysis
Statistical analysis was performed with SPSS 18.0 software. Data are expressed as mean ± standard deviation. All experiments were performed in triplicate. The differences in expression levels of leptin, ERα and ERβ as well as quantity of secreted leptin between the control and treated cells were analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison tests. A p-value <0.05 was considered as significant.

Results

MTT assay
Data analysis of cytotoxicity assay showed that IC50 of curcumin on T47D breast cancer cell line was 28 and 24 μM for 24 and 48 h MTT assays, respectively (Figure 1). The obtained IC50s were dose-dependent.

Quantitative real-time PCR
Real-time PCR results showed a significant decrease in leptin expression in the treated cells compared to the control cells (p-value < 0.05) (Figure 2). We, also, measured the expression levels of ERα, and ERβ in the treated and control cells. Although, no significant difference was detected in ERβ expression levels between the treated and the control cells, a significant decrease was observed in the ERα mRNA level (p-value < 0.05) (Figure 3). Therefore, the ERα/ERβ expression ratio has been decreased in the treated cells compared to the control cells. There was no significant difference between the DMSO control and the DMSO-free control (the 0 μM concentration of curcumin).

Data analysis revealed a positive significant link between leptin gene expression and ERα gene expression level and no link between leptin and ERβ expression level in curcumin treated cells compared to the control cells. In addition, a positive significant correlation was found between mRNA level of leptin and ERα/ERβ expression ratio.

Measurement of secreted leptin
Amounts of secreted leptin were evaluated using ELISA. A significant difference was found between the control and treated cells in term of secreted leptin (Figure 4). This finding was in accordance with inhibition of leptin gene expression by curcumin.

Discussion
This study demonstrates that curcumin, most active constituent of turmeric, can inhibit leptin gene expression and secretion in T47D breast cancer cells and this decrease in leptin gene expression and secretion was positively associated with decrease of ERα gene expression. These results indicate that curcumin has a strong potential to interact with the expression of leptin gene, which has significant roles in carcinogenesis and proliferation of breast cancer cells [2]. Regarding to the critical role of leptin in breast carcinogenesis [24], there are many attempts to inhibit leptin function and secretion. Gonzalez et al. inhibited growth of murine mammary cancer cell and xenograft tumor model of human breast cancer cell lines by leptin peptide antagonist [25]. In addition, leptin analog mimicking its action [26] and anti-leptin receptor monoclonal antibody [27] are also another approaches for interfering with the leptin function. In the other studies, administrations of some compounds including b3-adrenoceptor agonist, conjugated linoleic Acid, isoflavone, resveratrol and bitter melon lead to decreased secretion and lower levels of serum leptin [28]. The current work, however, aimed to direct inhibition of leptin expression and secretion in human
T47D breast cancer cell line using curcumin. Due to significant anti-cancer effects of curcumin on various types of cancers such as gastrointestinal, genitourinary, gynecological, hematological, pulmonary, thymic, brain, breast, and bone [29], it can be used as a chemotherapeutic agent for breast cancer therapy.

The mechanisms by which curcumin exerts its anti-cancer effects are comprehensive and diverse, targeting many levels of regulation in the processes of cellular growth and apoptosis. Curcumin has an inhibitory effect on both NF-κB and AP-1 activation. Curcumin has been shown to suppress the expression of a variety of NF-κB regulated gene products involved in carcinogenesis and tumor growth including cyclin D1, VEGF, COX-2, c-myc, Bcl-2, ICAM-1 and MMP-9 [30]. In addition, Curcumin has been shown to suppress the expression of cyclin D1 in many types of cancer including head and neck, colon, bladder, breast, cervical and pancreatic carcinomas [31]. Our results, regarding inhibition of leptin expression, confirm these findings, also demonstrating another role for curcumin effect that probably acts through estrogen receptors. It has been demonstrated that expression of leptin has positive correlation with expression of ERα and negative correlation with ERβ expression [32]. In addition, leptin promoter has response elements for both ERα and ERβ [33]; where, probably competition between ERα and ERβ in attachment to this place causes reduction of leptin gene transcription by

Figure 3 Effect of curcumin on expression levels of ERα (A) and ERβ (B) genes in the T47D cells. As the figure shows, there is a significant decrease in ERα gene expression levels with increasing in the curcumin concentration (p-value < 0.05), unlike ERβ gene expression levels.

Figure 4 Effect of curcumin on leptin secretion in T47D cells.
lowered activity of the leptin promoter. Nejati-Koshki et al. reported that silybin can decrease leptin gene expression and secretion in T47D cells thought activation of ERβ gene expression [34]. In the current study, we showed that reduction of leptin expression by curcumin positively correlates with expression of ERα. Therefore, it seems that one of the possible mechanisms of curcumin inhibitory effect on leptin expression could be through ERs. However, many studies need to determine the exact molecular mechanism(s) involved in the reduction of leptin gene expression and secretion by curcumin [35–34].

**Conclusion**

In summary, we demonstrated that curcumin could inhibit expression and secretion of leptin in T47D breast cancer cells. Regarding to the significant roles of leptin in breast carcinogenesis, its inhibition could be considered as a novel strategy for treatment of breast cancer in the future.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SWL conceived the study and participated in its design and coordination. AA participated in the sequence alignment and drafted the manuscript. YH, and KNK helped in drafting the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

The authors would like to thanks Faculty of advanced medical sciences for granting and technical assistance.

**Author details**

'1Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 2Department of Nanobiotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 3Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

**Received:** 11 March 2014 **Accepted:** 28 April 2014 **Published:** 23 December 2014

**References**

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10–29.
2. Vona-Davis L, Rose DP: Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14(2):189–206.
3. Zhang Y, Provencio R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(6505):425–432.
4. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS: Role of leptin in fat regulation. Nature 1996, 380(6576):67.
5. Fantuzzi G, Faggioni R: Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2001, 68(4):437–446.
6. Löffler S, Aust G, Köhler U, Spanel-Borowski K: Evidence of leptin expression in normal and polycystic human ovaries. Mol Hum Reprod 2001, 7(12):1143–1149.
7. Soyupek S, Armagan A, Serel TA, Hoşcan MB, Perk H, Karalez L, Candir O: Leptin expression in the testicular tissue of fertile and infertile men. Arch Androl 2005, 51(3):239–246.
8. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, Nakao K: Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997, 3(9):1029–1033.
9. Morroni M, De Matteis R, Palumbo C, Ferretti M, Villa I, Rubinacci A, Cinti S, Marotti G: In vivo leptin expression in cartilage and bone cells of growing rats and adult humans. J Anim 2004, 208(4):291–296.
10. Solberg R, Asv Thoresen GH, Kase ET, Drevon CA, Rusan AC, Reseland JE: Leptin expression in human primary skeletal muscle cells is reduced during differentiation. J Cell Biochem 2005, 96(1):89–96.
11. Mix H, Widjaja A, Jandl O, Cornberg M, Kaul A, Göke M, Beil W, Kuske M, Brabant G, Manns MP, Wagner S: Expression of leptin and leptin receptor isoforms in the human stomach. Gut 2002, 47(4):481–486.
12. Oda A, Taniguchi T, Yokoyama M: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001, 47(3):141–150.
13. Hardwick JC, Van Den Bink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP: Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001, 121(1):79–90.
14. Elizondo NR, Buitrago AM, Tiscornia G, Nishimura H, Hannon GL, Hidalgo DA, Sánchez-Vázquez-Mendieta M, Sánchez-Escobar C, Fernández-Gutiérrez A, González S, Borroto-Bermúdez F, Hernández-García M, Hernández-Bautista J, Luna-González A, Carmona-Pérez C, Hernández-Martínez M, León T, Peinado-Sánchez M: Leptin expression and secretion in T47D breast cancer cell line. Mol Cell Endocrinol 2002, 188(1–2):219–226.
15. Hu X, Janeca SC, Mahile NL, Cleary MP: Leptin—a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2004, 96(22):1704–1711.
16. Tanggara L, Coughlin M: Leptin receptor. J Biol Chem 1997, 272(16):6903–6906.
17. Itikawa M, Kiyarayo K, Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004, 10(1):4325–4331.
18. Koda M, Sulkovska M, Kanczuga-Koda L, Jarzabek K, Sulkowski S: Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folio Histochem Cytochem 2007, 45(Suppl 1):S187–S191.
19. Shin JH, Hur JY, Seo HS, Jeong YA, Lee JK, Oh MJ, Kim T, Saw HS, Kim SH: The ratio of estrogen receptor alpha to estrogen receptor beta in adipose tissue is associated with leptin production and obesity. Steroids 2007, 72(6):592–599.
20. Micev M, Wahid F, Jin YS: Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010, 343(9):489–499.
21. Pourhassan M, Zargarhani N, Rahmani M, Alikhaski A, Ranjbari R: The inhibitory effect of Curcuma longa extract on telomerase activity in A549 lung cancer cell line. Afr J Biotechnol 2010, 9(6):912–919.
22. Gorafalo C, Surmacz E: Leptin and cancer. J Cell Physiol 2006, 207(1):12–22.
23. Gonzalez RR, Watters A, Xu Y, Singh UP, Mann DR, Ruiva BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009, 11(3):S35.
24. Peters JH, Simasko SM, Ritter RC: Leptin analog antagonizes leptin effects on food intake and body weight but mimics leptin-induced vagal afferent activation. Endocrinology 2007, 148(8):3726–3735.
25. Fazeli M, Zarkesh-Esfahani H, Wu Z, Maamra M, Böllingmaier M, Pindley AG, Watson P, Matarese G, Strasser CJ, Ross RJ: Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods 2006, 312(1):190–200.
26. Ray A, Cleary MP: Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010, 14(4):443–451.
27. Nejati-Koshki et al. Cancer Cell International 2014, 14:66 http://www.cancerCi.com/content/14/1/66 Page 6 of 7
28. Fazeli M, Zarkesh-Esfahani H, Wu Z, Maamra M, Böllingmaier M, Pindley AG, Watson P, Matarese G, Strasser CJ, Ross RJ: Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods 2006, 312(1):190–200.
29. Ray A, Cleary MP: Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010, 14(4):443–451.
30. Shehzad A, Lee J, Lee YS: Curcumin in various cancers. Biofactors 2013, 35:166–68.
31. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, Aggarwal BB: Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009, 125(2):1871–191.
31. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silybin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Mol Cancer Ther 2009, 8(6):1606–1612.

32. Yi W, Shin JH, Seo HS, Lee JX, Oh MJ, Kim T, Saw HS, Kim SH, Hur JY. Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3 T3-L1 adipocytes. Obesity (Silver Spring) 2008, 16(11):2393–2399.

33. O’Neil JS, Burov ME, Green AE, McLachlan JA, Henson MC. Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta. Mol Cell Endocrinol 2001, 176(1-2):17–75.

34. Nejati-Koshki K, Zarghami N, Pourhassan-Moghadam M, Rahmati-Yamchi M, Mollazade M, Nasiri M, Esfahan RJ, Barkhordari A, Tayefi-Nasrabadi H. Inhibition of leptin gene expression and secretion by silybin: possible role of estrogen receptors. Cyto technology 2012, 64(7):719–726.

35. Akbarzadeh A, Mikaei H, Asgari D, Zarghami N, Mohammad M, Davaran S. Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine 2012, 7(5):511–526.

36. Akbarzadeh A, Zarghami N, Mikaei H, Asgari D, Amir Mohammad G, Khakar Khabiani H, Soodeabed D. Synthesis, characterization and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Int J Nanotechnol Sci Environ 2012, 8(13–25).

37. Akbarzadeh A, Samiei M, Joo SW, Anzaby S, Hamid Tayefi N, Alibakhshi A. Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol 2012, 10(46–58).

38. Zohreh E, Nosratollah Z, Manoutchehri K, Soumaya A, Abolfazl A, Mohammad R, Zohreh Mohammad T, Kazem N-K. Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line. Biomips 2013, 3(2):67–74.

39. Davaran S, Alimohammadi S, Nejati-Koshki K, Hamid Tayefi N, Abolfazl A, Amir Ahmad K, Mojtaba A, Somayeh A. Synthesis and study of physicochemical characteristics of Fe3O4 magnetic monocomplexes based on poly (Nisopropylacrylamide) for anti-cancer drugs delivery. Asian Pac J Cancer Prev 2014, 15(1):049–054.

40. Rogaei R-S, Nosratollah Z, Abolfazl B, Akram E, Abolfazl A, Mustafa R-T. Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxystyrol derivatives indicated by quantum chemical calculations. Soft 2013, 2:13–18.

41. Nejati-Koshki K, Akbarzadeh A, Pourhassan-Moghadam M, woo joo s. Inhibition of leptin and leptin receptor gene expression by silybin-curcumin combination. Asian Pac J Cancer Prev 2013, 14(1):6595–6599.

42. Ghasemi S, Nejati-Koshki K, Akbarzadeh A, Tastofi E, Zarghami N, Rahmati-Yamchi M, Alizadeh E, Barkhordari A, Tozli M, Kordi S. Study of inhibitory effect of β-Cyclodextrin-HelenalinComplex on HTERT Gene Expression in T47D breast cancer cell line by Real TimeQuantitative PCR (q-PCR). Asian Pac J Cancer Prev 2013, 14(1):6945–6952.

43. Mollazade M, Nejati-Koshki K, Abolfazl A, Younes H, Zarghami N, Sang Woo J. PAMAM Dendrimers arugment inhibitory effect of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev 2013, 14(3):3449–3453.

44. Davaran S, Rezaei A, Alimohammadi S, Amir Ahmad K, Kazem N-K, Hamid Tayefi N, Abolfazl A. Synthesis and Physicochemical Characterization of Biodegradable star-shaped poly lactide-coge-clyclic–β – cyclodextrin copolymer Nanoparticles Containing Albumin. Adv Nanoparticles 2014, 3:14–22.

45. Davaran S, Abolfazl Akbarzadeh1, Kazem N-K, Somayeh A, Mahmoudi S, Akbarzadeh A, In vitro studies of NIPAAM-MAA-VP copolymer-coated magnetic nanoparticles for controlled anticancer drug release. J Encapsulation Adsorption Sci 2013, 3:108–115.

46. Nasiri M, Zarghami N, Koshki KN, Mollazade M, Moghadam MP, Yamechi MR, Esfahan RJ, Barkhordari A, Alibakhshi A. Curcumin and silybin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev 2013, 14(6):3449–3453.

47. Abolfazl A, Samiei M, Soodeabed D. Magnetic nanoparticles: preparation, physical properties and applications in biomedicine. Nanoscale Res Lett 2012, 7:144–157.

48. Alineva V, Haleb M, Mohammad S, Samed Musa F, Nosratollah Z, Mohammad K, Abolfazl A, Soodeabed D. Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res Lett 2012, 7:2178.

49. Abolfazl A, Rogaei R-S, Soodeabed D, Sang Woo J, Nosratollah Z, Younes H, Mohammad S, Mohammad K, Kazem N-K. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013, 8:102.

50. Mohammad P-M, Mohammad R-Y, Abolfazl A, Hadi S, Kazem N-K, Younes H, Sang Woo J. Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett 2013, 8:495.

51. Ebrahiminezhad Z, Zarghami N, Keyhani M, Amirsadaat S, Akbarzadeh A, Rahmati M, Mohammad Taheri Z, Nejati-Koshki K. Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line. Biomips 2013, 3(2):67–74.

52. Pourhassan-Moghadam M, Rahmati-Yamchi M, Akbarzadeh A, Darake H, Nejati-Koshki K, Hanifehpour Y, Joo SW, Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett. 2013, 8(1):485.

53. Esfahan RJ, Zarghami N, Esfahan AJ, Mollazadeh M, Nejati K, Nasiri M. Basic of DNA biosensors and cancer diagnosis. The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERa and ERb) Gene Expression in Breast Cancer Patients. Breast Cancer (Auckl) 2011, 2:227–337.

54. Mirakabad FST, Akbarzadeh A, Zarghami N, Zeighamian V, Rahimzadeh A, Alimohammadi S. PLGA-Based nanoparticles as cancer drug delivery systems. AIPCP Asian Pac J Cancer Prev 2014, 15(1):517–535.